A new week, and another major achievement for CURLIM ! A few weeks ago, we announced our Orphan Drug Designation in Europe, and today, we’re proud to share that CURLIM has also obtained Orphan Drug Designation in the United States.…
We are proud to announce that CURLIM has been awarded as part of the 2024–2025 State Innovation Challenge, joining 147 projects supported by the French government under #France2030. This recognition marks a major milestone for CURLIM It reflects our determination…
We are pleased to announce that the European Commission, following a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted CLM001 orphan drug designation for the treatment of Charcot-Marie-Tooth disease (CMT).…